REG - CVS Group plc - Block Listing Interim Review and TVR Update

CVSAnnouncement

11/01/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230111:nRSK4416Ma&default-theme=true

RNS Number : 4416M  CVS Group plc  11 January 2023

11 January 2023

 

CVS Group plc

 

("CVS" or the "Company")

 

Block Listing Interim Review and TVR Update

CVS, one of the UK's leading providers of integrated veterinary services,
makes the following notification pursuant to Schedule Six of the AIM Rules for
Companies regarding its existing block listing arrangements.  References to
securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary
Shares").

 Name of the company:                                                              CVS Group plc

 Name of relevant scheme:                                                          1.     CVS Group plc 2017-2020 Sharesave Scheme;

                                                                                   2.     CVS Group plc 2018-2021 SAYE Sharesave Scheme; and

                                                                                   3.     CVS Group 2018 SAYE Plan

 Period of return:                        From:                                    12 July 2022              To:                       11 January 2023
 Balance of unallotted securities under scheme(s) from previous return:            1.    230

                                                                                   2.    19,598

                                                                                   3.    348,290
 Plus: The amount by which the block scheme(s) has been increased since the        1.    Nil
 date of the last return (if any increase has been applied for):

                                                                                   2.    Nil

                                                                                   3.    Nil
 Less:  Number of securities issued / allotted under scheme(s) during period:      1.    0

                                                                                   2.    6,734

                                                                                   3.    112,148
 Equals: Balance under scheme(s) not yet issued / allotted at end of period:       1.    230

                                                                                   2.    12,864

                                                                                   3.    236,142
 Number and class of securities originally listed and the date of admission:       1.    114,302 Ordinary Shares admitted on 11 January 2021 and 1,535
                                                                                   Ordinary Shares admitted on 1 September 2021

                                                                                   2.    296,069 Ordinary Shares admitted on 1 September 2021

                                                                                   3.    350,000 Ordinary Shares admitted on 30 December 2021

 

 

Total Voting Rights

The number of securities that have been issued during the block listing review
period stated above includes 106,955 new Ordinary Shares issued on 10 January
2023 in connection with the exercise of employee share options under the CVS
Group plc 2019-2023 SAYE Sharesave Scheme and a further 1,474 new Ordinary
Shares issued on 10 January 2023 in connection with the exercise of employee
options under the CVS Group plc 2018-2022 SAYE Sharesave Scheme.

Following the issue of these new Ordinary Shares, which rank pari passu in all
respects with the Company's existing Ordinary Shares, the Company has a total
issued share capital of 71,380,400 Ordinary Shares, each carrying one voting
right.  The Company holds no Ordinary Shares in treasury so the total number
of voting rights is therefore 71,380,400.

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest, or a change to their interest, in the Company under the FCA's
Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group
plc
via Camarco

Richard Fairman, CEO

Jenny Farrer, Company Secretary

 

Peel Hunt LLP (Nominated Adviser &
Broker)
+44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

   Berenberg (Joint
Broker)
+44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial
PR)

Geoffrey
Pelham-Lane
                     +44 (0)7733 124 226

Ginny
Pulbrook
  +44 (0)7961 315 138

   Toby
Strong
+44 (0)7789 151 644

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBLGDBIDBDGXB